333 related articles for article (PubMed ID: 30228232)
1. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
[TBL] [Abstract][Full Text] [Related]
2. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
3. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
5. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
Cippitelli M; Stabile H; Kosta A; Petillo S; Gismondi A; Santoni A; Fionda C
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499314
[TBL] [Abstract][Full Text] [Related]
6. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
7. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
8. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
9. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK
Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
11. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation.
Mazzurana L; Forkel M; Rao A; Van Acker A; Kokkinou E; Ichiya T; Almer S; Höög C; Friberg D; Mjösberg J
Eur J Immunol; 2019 Sep; 49(9):1344-1355. PubMed ID: 31151137
[TBL] [Abstract][Full Text] [Related]
13. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
14. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
[TBL] [Abstract][Full Text] [Related]
15. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
[TBL] [Abstract][Full Text] [Related]
16. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
17. IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.
Goh W; Sudholz H; Foroutan M; Scheer S; Pfefferle A; Delconte RB; Meng X; Shen Z; Hennessey R; Kong IY; Schuster IS; Andoniou CE; Davis MJ; Hediyeh-Zadeh S; Souza-Fonseca-Guimaraes F; Parish IA; Beavis P; Thiele D; Chopin M; Degli-Esposti MA; Cursons J; Kallies A; Rautela J; Nutt SL; Huntington ND
Nat Immunol; 2024 Feb; 25(2):240-255. PubMed ID: 38182668
[TBL] [Abstract][Full Text] [Related]
18. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
19. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
